中性粒细胞百分比、淋巴细胞百分比对肺腺癌EGFR-TKI靶向治疗预后的预测价值  

Prognosis assessment value of neutrophil percentage and lymphocyte percentage for lung adenocarcinoma patients with EGFR-TKI targeted therapy

作　　者：席颖[1] 张腾飞[1] 余军林 耿一萌 杜雅冰[1] 崔抗[1] 马望[1] XI Ying;ZHANG Tengfei;YU Junlin;GENG Yimeng;DU Yabing;CUI Kang;MA Wang(Department of Oncology,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 45005)

机构地区：[1]郑州大学第一附属医院肿瘤科,郑州450052

出　　处：《郑州大学学报（医学版）》2018年第5期619-622,共4页Journal of Zhengzhou University(Medical Sciences)

基　　金：国家自然科学基金面上项目(31570917)

摘　　要：目的:探讨中性粒细胞百分比、淋巴细胞百分比对肺腺癌表皮生长因子受体-酪氨酸激酶抑制剂(EGFRTKI)靶向治疗预后的预测价值。方法:收集162例接受EGFR-TKI靶向治疗的肺腺癌患者的治疗资料和随访资料,采用Cox回归模型分析预后的影响因素。结果:162例中,18、19、20、21位点突变分别有4、81、11和66例。治疗前162例患者中性粒细胞百分比(62.90±12.58)%,其中在正常范围130例,降低8例,升高24例;淋巴细胞百分比(25.39±10.89)%,其中在正常范围102例,降低48例,升高12例。Cox回归分析结果显示,以EGFR基因突变类型为分层因素,在调整年龄、性别因素后,治疗前淋巴细胞百分比升高可降低肺腺癌EGFR-TKI靶向治疗的不良预后风险(HR=0.934,95%CI为0.884~0.987)。结论:淋巴细胞百分比可能是一个重要的肺癌EGFR-TKI靶向治疗预后预测因子。Aim： To investigate the prognosis assessment value of neutrophil percentage and lymphocyte percentage for lung adenocarcinoma patients with EGFR-TKI targeted therapy. Methods：The data of 162 lung adenocarcinoma patients treated with EGFR-TKI were analyzed retrospectively. The relationship between neutrophil percentage,lymphocyte percentage and prognosis was assessed by Cox regression analysis. Results：Out of the 162 cases,there were 4,81,11 and 66 mutation cases at positions 18,19,20 and 21,respectively. Before treatment,the neutrophil percentage in 162 patients was（62. 90 ± 12. 58）%,in which 130 cases were normal,8 were decreased,and 24 were increased;the lymphocyte percentage was（25. 39 ± 10. 89） %,in which 102 cases were normal,48 were decreased,and 11 were increased. Cox regression analysis showed that,with EGFR gene mutation as a stratification factor,after adjusting age and gender,the increase of pretreatment lymphocyte percentage could reduce the adverse prognosis risk（ HR = 0. 934,95% CI was 0. 884 to 0. 987）. Conclusion： Lymphocyte percentage may be an important biomarker for the prognosis assessment of lung adenocarcinoma patients with EGFR-TKI targeted therapy.

关 键 词：表皮生长因子受体-酪氨酸激酶抑制剂 肺腺癌 中性粒细胞百分比 淋巴细胞百分比 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]